Identification

Name
Zaltoprofen
Accession Number
DB06737
Type
Small Molecule
Groups
Approved, Investigational
Description

A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.

Structure
Thumb
Synonyms
  • Zaltoprofen
  • Zaltoprofene
  • Zaltoprofeno
  • Zaltoprofenum
External IDs
CN 100 / CN-100 / ZC 102
International/Other Brands
Borbit (Yoshindo) / Peleton (Towa Yakuhin) / Peon (Zeria Shinyaku) / Salafapinon (Choseido Pharmaceutical) / Soleng (Kyorin Rimedio) / Soleton (CJ Cheiljedang) / Soluirubin (Taiyo Pharmaceutical) / Zaltoprofen Tatsumi Kagaku (Tatsumi Kagaku) / Zatferon (Sawai Seiyaku) / Zyrogen (Yoo Young)
Categories
UNII
H8635NG3PY
CAS number
74711-43-6
Weight
Average: 298.36
Monoisotopic: 298.066365485
Chemical Formula
C17H14O3S
InChI Key
MUXFZBHBYYYLTH-UHFFFAOYSA-N
InChI
InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
IUPAC Name
2-{10-oxo-2-thiatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-6-yl}propanoic acid
SMILES
CC(C(O)=O)C1=CC=C2SC3=C(C=CC=C3)C(=O)CC2=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabZaltoprofen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Zaltoprofen can be decreased when combined with Abiraterone.Approved
AcebutololZaltoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Zaltoprofen.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolZaltoprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zaltoprofen.Approved, Vet Approved
AclarubicinZaltoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Zaltoprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aldosterone.Experimental, Investigational
AldoxorubicinZaltoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid.Approved
AliskirenZaltoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alminoprofen.Experimental
AlprenololZaltoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Zaltoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Amcinonide.Approved
AmikacinZaltoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideZaltoprofen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Zaltoprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinZaltoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodZaltoprofen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Zaltoprofen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anisodamine.Investigational
AnnamycinZaltoprofen may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zaltoprofen.Approved, Investigational
Antithrombin III humanZaltoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
ApalutamideThe serum concentration of Zaltoprofen can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanZaltoprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Apocynin.Investigational
ApramycinZaltoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Zaltoprofen.Approved, Investigational
AprepitantThe metabolism of Zaltoprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinZaltoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinZaltoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanZaltoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololZaltoprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Atamestane.Investigational
AtenololZaltoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zaltoprofen.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zaltoprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Zaltoprofen.Investigational
BalsalazideZaltoprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminZaltoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololZaltoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinZaltoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zaltoprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zaltoprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zaltoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololZaltoprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Zaltoprofen.Approved, Investigational
BevantololZaltoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
BisoprololZaltoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinZaltoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololZaltoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zaltoprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bucillamine.Investigational
BucindololZaltoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bufexamac.Approved, Experimental
BufuralolZaltoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Zaltoprofen.Approved
BupranololZaltoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Zaltoprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zaltoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Zaltoprofen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Captopril.Approved
CarbamazepineThe metabolism of Zaltoprofen can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zaltoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Zaltoprofen.Approved, Vet Approved, Withdrawn
CarteololZaltoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolZaltoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zaltoprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Celecoxib.Approved, Investigational
CeliprololZaltoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Zaltoprofen can be increased when it is combined with Ceritinib.Approved
CertoparinZaltoprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zaltoprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zaltoprofen.Approved
CholecalciferolThe metabolism of Zaltoprofen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zaltoprofen.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cilazapril.Approved
CinoxacinZaltoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidZaltoprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Zaltoprofen.Vet Approved
CloranololZaltoprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Zaltoprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Zaltoprofen can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zaltoprofen.Experimental
CyclosporineZaltoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateZaltoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Zaltoprofen can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinZaltoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidZaltoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanZaltoprofen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinZaltoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Delapril.Experimental
DelavirdineThe metabolism of Zaltoprofen can be decreased when combined with Delavirdine.Approved
DesirudinZaltoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zaltoprofen.Approved, Investigational
DextranZaltoprofen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Zaltoprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Zaltoprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Zaltoprofen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinZaltoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zaltoprofen.Approved, Vet Approved
DicoumarolZaltoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zaltoprofen.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Zaltoprofen.Approved
DihydrostreptomycinZaltoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Zaltoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zaltoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Zaltoprofen.Approved
DosulepinThe metabolism of Zaltoprofen can be decreased when combined with Dosulepin.Approved
DoxorubicinZaltoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneZaltoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Zaltoprofen is combined with E-6201.Investigational
Edetic AcidZaltoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanZaltoprofen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Zaltoprofen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalaprilat.Approved
EnoxacinZaltoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinZaltoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Zaltoprofen.Experimental
EpanololZaltoprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Epirizole.Approved
EpirubicinZaltoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Zaltoprofen.Experimental
EplerenoneZaltoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zaltoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zaltoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilin.Approved
EsmololZaltoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zaltoprofen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Zaltoprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateZaltoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Zaltoprofen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Zaltoprofen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zaltoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Zaltoprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Feprazone.Experimental
Ferulic acidZaltoprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zaltoprofen.Approved, Investigational
FleroxacinZaltoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Zaltoprofen.Approved, Withdrawn
FloxuridineThe metabolism of Zaltoprofen can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Zaltoprofen can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fludrocortisone.Approved, Investigational
FluindioneZaltoprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineZaltoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Zaltoprofen can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Zaltoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zaltoprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Zaltoprofen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Zaltoprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zaltoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxZaltoprofen may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumZaltoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Zaltoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Zaltoprofen can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinZaltoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Zaltoprofen.Approved, Vet Approved
GabexateZaltoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinZaltoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinZaltoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Zaltoprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Zaltoprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinZaltoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinZaltoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinZaltoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AZaltoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Zaltoprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinZaltoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Zaltoprofen is combined with HE3286.Investigational
HeparinZaltoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Higenamine.Investigational
HydralazineZaltoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
Hygromycin BZaltoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zaltoprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Zaltoprofen.Approved, Investigational
IdarubicinZaltoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxZaltoprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zaltoprofen.Approved
IndenololZaltoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Zaltoprofen can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zaltoprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indoprofen.Withdrawn
IrbesartanThe metabolism of Zaltoprofen can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinZaltoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Istaroxime.Investigational
KanamycinZaltoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Zaltoprofen can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zaltoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zaltoprofen.Approved
LabetalolZaltoprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololZaltoprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Zaltoprofen.Approved, Investigational
LeflunomideThe metabolism of Zaltoprofen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinZaltoprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanZaltoprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololZaltoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinZaltoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Zaltoprofen.Approved
LobeglitazoneThe metabolism of Zaltoprofen can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zaltoprofen.Approved, Investigational
LosartanThe metabolism of Zaltoprofen can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loteprednol.Approved
LovastatinThe metabolism of Zaltoprofen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zaltoprofen.Approved, Investigational
LumacaftorThe serum concentration of Zaltoprofen can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Zaltoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zaltoprofen.Approved
ManidipineThe metabolism of Zaltoprofen can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zaltoprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Zaltoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zaltoprofen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zaltoprofen.Approved
MelagatranZaltoprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zaltoprofen.Approved, Vet Approved
MepindololZaltoprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineZaltoprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Zaltoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololZaltoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen.Approved
MetoprololZaltoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideZaltoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinZaltoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Zaltoprofen can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Zaltoprofen.Approved, Experimental
MifepristoneThe serum concentration of Zaltoprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zaltoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zaltoprofen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zaltoprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nabumetone.Approved
NadololZaltoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinZaltoprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatZaltoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Zaltoprofen.Approved
Nalidixic AcidZaltoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Zaltoprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Zaltoprofen is combined with NCX 1022.Investigational
NeamineZaltoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololZaltoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinZaltoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinZaltoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zaltoprofen.Approved, Investigational
NetilmicinZaltoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Zaltoprofen can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zaltoprofen.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nitroaspirin.Investigational
NorfloxacinZaltoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zaltoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen.Approved
OlsalazineZaltoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Zaltoprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Zaltoprofen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Orgotein.Vet Approved
OtamixabanZaltoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zaltoprofen.Approved
Oxolinic acidZaltoprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololZaltoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parecoxib.Approved
ParomomycinZaltoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parthenolide.Approved, Investigational
PazufloxacinZaltoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinZaltoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololZaltoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateZaltoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateZaltoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Perindopril.Approved
PhenindioneZaltoprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Zaltoprofen can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonZaltoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zaltoprofen.Approved, Vet Approved
PhenytoinThe metabolism of Zaltoprofen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zaltoprofen.Approved, Investigational
PindololZaltoprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidZaltoprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinZaltoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Zaltoprofen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zaltoprofen.Approved, Investigational
Piromidic acidZaltoprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zaltoprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorZaltoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinZaltoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinZaltoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zaltoprofen.Approved
PractololZaltoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Zaltoprofen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Zaltoprofen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Zaltoprofen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propacetamol.Approved, Investigational
PropranololZaltoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Zaltoprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Zaltoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Zaltoprofen.Vet Approved
Protein CZaltoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanZaltoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeZaltoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinZaltoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Zaltoprofen.Investigational
PuromycinZaltoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Zaltoprofen can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zaltoprofen.Approved
QuinineThe metabolism of Zaltoprofen can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zaltoprofen.Approved, Experimental, Investigational
ReviparinZaltoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinZaltoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Zaltoprofen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Zaltoprofen can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanZaltoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinZaltoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Zaltoprofen can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinZaltoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinZaltoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Zaltoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Zaltoprofen.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Zaltoprofen.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zaltoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Zaltoprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Zaltoprofen.Approved, Investigational
SecobarbitalThe metabolism of Zaltoprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Zaltoprofen can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinZaltoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinZaltoprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Zaltoprofen.Approved
SorafenibThe metabolism of Zaltoprofen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolZaltoprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CZaltoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinZaltoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinZaltoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Spirapril.Approved
SpironolactoneZaltoprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Zaltoprofen.Investigational
StreptomycinZaltoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinZaltoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfadiazineThe metabolism of Zaltoprofen can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Zaltoprofen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zaltoprofen.Approved
SulfisoxazoleThe metabolism of Zaltoprofen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Zaltoprofen.Approved, Investigational
SulodexideZaltoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Zaltoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zaltoprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Suxibuzone.Experimental
TacrolimusZaltoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Zaltoprofen.Approved
TalinololZaltoprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Zaltoprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Zaltoprofen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zaltoprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zaltoprofen.Approved, Investigational
TemafloxacinZaltoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zaltoprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Teriflunomide.Approved
TertatololZaltoprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zaltoprofen.Approved
TicagrelorThe metabolism of Zaltoprofen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Zaltoprofen can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololZaltoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinZaltoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Zaltoprofen can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zaltoprofen.Approved
TopiroxostatThe metabolism of Zaltoprofen can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Zaltoprofen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zaltoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zaltoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneZaltoprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zaltoprofen.Approved, Vet Approved
TrimethoprimThe metabolism of Zaltoprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triptolide.Investigational
TrovafloxacinZaltoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinZaltoprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Zaltoprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinZaltoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Zaltoprofen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Zaltoprofen.Approved
VoriconazoleThe metabolism of Zaltoprofen can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinZaltoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranZaltoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zaltoprofen can be decreased when combined with Zafirlukast.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Zaltoprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zaltoprofen.Withdrawn
Zoptarelin doxorubicinZaltoprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinZaltoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13. [PubMed:16473424]
External Links
KEGG Drug
D01547
PubChem Compound
5720
PubChem Substance
347827786
ChemSpider
5518
ChEBI
32306
ChEMBL
CHEMBL1765291

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusTreatmentInjuries, Whiplash1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP3.55ALOGPS
logP3.76ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)3.67ChemAxon
pKa (Strongest Basic)-7.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity83.69 m3·mol-1ChemAxon
Polarizability31.16 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzothiepins. These are compounds containing a dibenzothiepin moiety, which consists of two benzene connected by a thiepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiepins
Sub Class
Dibenzothiepins
Direct Parent
Dibenzothiepins
Alternative Parents
Diarylthioethers / Aryl alkyl ketones / Vinylogous thioesters / Benzenoids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Dibenzothiepin / Diarylthioether / Aryl thioether / Aryl ketone / Aryl alkyl ketone / Benzenoid / Vinylogous thioester / Ketone / Thioether / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Drug created on August 31, 2010 14:54 / Updated on March 02, 2018 03:12